Congress Presentations

Posters

• Dolutegravir
• Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis.
• Is DTG+3TC effective and safe in clinical practice? Evidence from real world data.
• Weight change among treatment naive women initiating dolutegravir in the ARIA study.
• Comparison of viral replication at <40c/mL for 2-drug regimen (2DR) of dolutegravir/lamivudine (DTG/3TC FDC) versus 3-drug regimen (3DR) based on tenofovir alafenamide (TAF) (TBR) in the TANGO study.
• Cabotegravir
• Perceived implementation barriers decrease during initial stages of the first implementation science hybrid III study (CUSTOMIZE) of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in US healthcare settings: Healthcare team perspective.
• Patient-reported outcomes through week 48 of ATLAS-2M: A study of long-acting cabotegravir and rilpivirine administered every four or eight weeks.
• Compassionate use of long acting (LA) cabotegravir (CAB) and rilpivirine (RPV) for patients in need of parenteral antiretroviral therapy.
• Feasibility of implementing long-acting injectable anti-retroviral therapy to treat HIV: A survey of health providers from the 13 countries participating in the ATLAS-2M trial.
• HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW).
• Fostemsavir
• Model-based approach of dose selection and optimal PK sampling of fostemsavir for pediatric patients with multidrug resistant HIV-1 infection.
• Clinical outcomes of heavily treatment experienced individuals in the OPERA Cohort.
• Disease State
• Factors associated with resilience among older people living with HIV.
• To dose-adjust or not to dose-adjust: 3TC dose in renal impairment.
• A tale of two "U" s and their use by healthcare providers: A cross-country analysis of information-sharing about 'Undetectable = Untransmittable' (U=U).
• Putting the heart back into HAART: Greater HCP-Patient engagement is associated with better health outcomes among persons living with HIV (PLHIV) on treatment.
• Characteristics of people with HIV (PWH) and HIV treatment outcomes in community practices in southern vs non-southern US regions.
• Effects of a nurse-delivered cognitive behavioral therapy on adherence and depressive symptoms of people living with HIV in South Korea.
• Understanding the changing treatment concerns of older people living with HIV and difficulties with patient-provider communication.
• Clinic staff members' perceptions of barriers to HIV care in the rural southern United States.